Suppr超能文献

神经病理学定义的具有不同临床特征的阿尔茨海默病亚型:一项回顾性研究。

Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study.

机构信息

Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.

出版信息

Lancet Neurol. 2011 Sep;10(9):785-96. doi: 10.1016/S1474-4422(11)70156-9. Epub 2011 Jul 27.

Abstract

BACKGROUND

Neurofibrillary pathology has a stereotypical progression in Alzheimer's disease (AD) that is encapsulated in the Braak staging scheme; however, some AD cases are atypical and do not fit into this scheme. We aimed to compare clinical and neuropathological features between typical and atypical AD cases.

METHODS

AD cases with a Braak neurofibrillary tangle stage of more than IV were identified from a brain bank database. By use of thioflavin-S fluorescence microscopy, we assessed the density and the distribution of neurofibrillary tangles in three cortical regions and two hippocampal sectors. These data were used to construct an algorithm to classify AD cases into typical, hippocampal sparing, or limbic predominant. Classified cases were then compared for clinical, demographic, pathological, and genetic characteristics. An independent cohort of AD cases was assessed to validate findings from the initial cohort.

FINDINGS

889 cases of AD, 398 men and 491 women with age at death of 37-103 years, were classified with the algorithm as hippocampal sparing (97 cases [11%]), typical (665 [75%]), or limbic predominant (127 [14%]). By comparison with typical AD, neurofibrillary tangle counts per 0.125 mm(2) in hippocampal sparing cases were higher in cortical areas (median 13, IQR 11-16) and lower in the hippocampus (7.5, 5.2-9.5), whereas counts in limbic-predominant cases were lower in cortical areas (4.3, 3.0-5.7) and higher in the hippocampus (27, 22-35). Hippocampal sparing cases had less hippocampal atrophy than did typical and limbic-predominant cases. Patients with hippocampal sparing AD were younger at death (mean 72 years [SD 10]) and a higher proportion of them were men (61 [63%]), whereas those with limbic-predominant AD were older (mean 86 years [SD 6]) and a higher proportion of them were women (87 [69%]). Microtubule-associated protein tau (MAPT) H1H1 genotype was more common in limbic-predominant AD (54 [70%]) than in hippocampal sparing AD (24 [46%]; p=0.011), but did not differ significantly between limbic-predominant and typical AD (204 [59%]; p=0.11). Apolipoprotein E (APOE) ɛ4 allele status differed between AD subtypes only when data were stratified by age at onset. Clinical presentation, age at onset, disease duration, and rate of cognitive decline differed between the AD subtypes. These findings were confirmed in a validation cohort of 113 patients with AD.

INTERPRETATION

These data support the hypothesis that AD has distinct clinicopathological subtypes. Hippocampal sparing and limbic-predominant AD subtypes might account for about 25% of cases, and hence should be considered when designing clinical, genetic, biomarker, and treatment studies in patients with AD.

FUNDING

US National Institutes of Health via Mayo Alzheimer's Disease Research Center, Mayo Clinic Study on Aging, Florida Alzheimer's Disease Research Center, and Einstein Aging Study; and State of Florida Alzheimer's Disease Initiative.

摘要

背景

神经纤维缠结病理学在阿尔茨海默病(AD)中具有典型的进展,这被包含在 Braak 分期方案中;然而,一些 AD 病例是非典型的,不符合该方案。我们旨在比较典型和非典型 AD 病例的临床和神经病理学特征。

方法

从脑库数据库中确定 Braak 神经纤维缠结分期超过 IV 期的 AD 病例。通过使用硫黄素-S 荧光显微镜,我们评估了三个皮质区域和两个海马扇区的神经纤维缠结的密度和分布。这些数据用于构建一种算法,将 AD 病例分为典型、海马保留或边缘优势。分类后的病例然后进行比较,以评估临床、人口统计学、病理学和遗传特征。对 AD 病例的独立队列进行评估,以验证初始队列的发现。

结果

889 例 AD 病例,398 名男性和 491 名女性,死亡年龄为 37-103 岁,通过算法分类为海马保留(97 例[11%])、典型(665 例[75%])或边缘优势(127 例[14%])。与典型 AD 相比,海马保留病例的皮质区域神经纤维缠结计数(中位数 13,IQR 11-16)每 0.125mm²更高,而海马区(7.5,5.2-9.5)则更低,而边缘优势病例的皮质区域(4.3,3.0-5.7)则更低,而海马区(27,22-35)则更高。海马保留病例的海马萎缩程度低于典型和边缘优势病例。海马保留 AD 患者的死亡年龄更年轻(平均 72 岁[SD 10]),且更多为男性(61[63%]),而边缘优势 AD 患者的年龄更大(平均 86 岁[SD 6]),且更多为女性(87[69%])。微管相关蛋白 tau(MAPT)H1H1 基因型在边缘优势 AD(54[70%])中比海马保留 AD(24[46%])更常见(p=0.011),但在边缘优势 AD 与典型 AD 之间差异不显著(204[59%])(p=0.11)。载脂蛋白 E(APOE)ɛ4 等位基因状态仅在按发病年龄分层时在 AD 亚型之间存在差异。临床表型、发病年龄、疾病持续时间和认知衰退速度在 AD 亚型之间存在差异。这些发现在 AD 患者的 113 例验证队列中得到了证实。

结论

这些数据支持 AD 具有不同临床病理亚型的假说。海马保留和边缘优势 AD 亚型可能占病例的约 25%,因此在设计 AD 患者的临床、遗传、生物标志物和治疗研究时应考虑这些亚型。

资助

美国国立卫生研究院通过梅奥诊所阿尔茨海默病研究中心、梅奥诊所衰老研究、佛罗里达阿尔茨海默病研究中心和爱因斯坦衰老研究;以及佛罗里达州阿尔茨海默病倡议。

相似文献

引用本文的文献

10

本文引用的文献

6
8
Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies.阿尔茨海默病和路易体痴呆中的磷酸化TDP-43
Acta Neuropathol. 2009 Feb;117(2):125-36. doi: 10.1007/s00401-008-0480-1. Epub 2009 Jan 13.
9
Biomarkers of Alzheimer's disease.阿尔茨海默病的生物标志物。
Neurobiol Dis. 2009 Aug;35(2):128-40. doi: 10.1016/j.nbd.2008.10.003. Epub 2008 Oct 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验